← Leaderboards
William Wilcox
La Biomed Res Inst/ Harbor Ucla Med Ctr
$237,978
Attributed
$237,978
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$237,978 · 2
By mechanism
M01$237,978 · 2
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- Margaret A Keller$2,116,833
- David L Rimoin$8,381,773
- Shalendar Bhasin$66,433,688
- Joel David Kopple$6,785,780
- Gildon N Beall$1,671,738
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchAchondroplasiaBone DevelopmentFibroblast Growth FactorGene MutationGrowth Factor ReceptorsFabry'S DiseaseHuman Therapy EvaluationAlpha Galactosidase
Grant awards (7)
EFFECT OF FGFR3 GENE MUTATION ON LINEAR BONE GROWTH$237,978
M01 · FY2001 · RR
EFFECT OF FGFR3 GENE MUTATION ON LINEAR BONE GROWTH$0
M01 · FY2000 · RR
EFFECT OF FGFR3 GENE MUTATION ON LINEAR BONE GROWTH$0
M01 · FY2000 · RR
EFFECT OF FGFR3 GENE MUTATION ON LINEAR BONE GROWTH$0
M01 · FY2000 · RR
Safety &efficacy of rhaGAL replacement in patients with Fabry's disease$0
M01 · FY2000 · RR
Safety &efficacy of rhaGAL replacement in patients with Fabry's disease$0
M01 · FY2000 · RR
Safety &efficacy of rhaGAL replacement in patients with Fabry's disease$0
M01 · FY2000 · RR